ArticleNature medicine2025
Blood-based biomarkers of Alzheimer's disease and incident dementia in the community.
Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Plasma Biomarkers for Alzheimer's Disease Across the Continuum: A Systematic Review of SIMOA-Based Studies.Cellular and molecular neurobiology · 2026Pooled it
- A critical review and classification of dementia risk assessment tools to inform dementia risk reduction.The journal of prevention of Alzheimer's disease · 2025Pooled it
- Neurobiological correlates of Mild Behavioral Impairment: a systematic review and meta-analysis.Alzheimer's research & therapy · 2025Pooled it
- Adaptive pathways for multimodal community-based detection of cognitive impairment: the CogScreen I study.Scientific reports · 2026Trial
- Alzheimer's blood-based biomarkers, incident dementia, and interactions with age, APOE status, and hormone therapy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Trial
- Plasma Phosphorylated Tau 217 and Incident Mild Cognitive Impairment and Dementia in Older Women.JAMA network open · 2026Trial
- A demographic perspective on longevity and healthspan: Rethinking population ageing through a positive and prospective lens.Journal of internal medicine · 2026Article
- Speech clocks decode dementia phenotypes, social exposome, and biological aging.Science advances · 2026Article
- Blood-based biomarkers of Alzheimer's disease and olfactory decline over 15 years in older adults.GeroScience · 2026Article
- Recent advances in Xanthone-based molecular hybrids: emerging therapeutic strategies for multifactorial diseases.Molecular diversity · 2026Review
- Oxidative stress and inflammation in neurodegenerative disorders.Archives of toxicology · 2026Review
- Article
- Enhancing Alzheimer's disease diagnosis in primary care through targeted screening of people at risk of developing dementia - study design and feasibility assessment of the PREDEM primary care study.Alzheimer's research & therapy · 2026Article
- Expert opinion on Alzheimer's disease diagnostics and management in Central Eastern European countries representing 88 million population.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Brain pathology in relation to somatic diseases: Exploring the body-brain crosstalk.Journal of internal medicine · 2026Review
- Beyond Amyloid: Hippocampal Atrophy as a Prognostic Marker in Amyloid-Negative Subjective Cognitive Decline.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Distinct ocular microvascular alterations in Alzheimer's disease and cerebral small vessel disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Plasma p-Tau217 and SPECT-Based eZIS in Mild Cognitive Impairment: Concordance Analysis with Validation in an Amyloid PET Sub-Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Corpus callosum fractional anisotropy from routine diffusion tensor imaging predicts dementia in older adults beyond clinical risk factors.GeroScience · 2026Article
- Blood Biomarkers of Alzheimer Disease and Rates of Global and Domain-Specific Cognitive Decline.JAMA network open · 2026Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Evidence regarding the clinical validity of blood biomarkers of Alzheimer's disease (AD) in the general population is limited. We estimated the hazard and predictive performance of six AD blood biomarkers for incident all-cause and AD dementia-the ratio of amyloid-β 42 to amyloid-β 40 and levels of tau phosphorylated at T217 (p-tau217), tau phosphorylated at T181 (p-tau181), total tau, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP)-in a cohort of 2,148 dementia-free older adults from Sweden, who were followed for up to 16 years. In multi-adjusted Cox regression models, elevated baseline levels of p-tau181, p-tau217, NfL, and GFAP were associated with a significantly increased hazard for all-cause and AD dementia, displaying a non-linear dose-response relationship. Elevated concentrations of p-tau181, p-tau217, NfL, and GFAP demonstrated strong predictive performance (area under the curve ranging from 70.9% to 82.6%) for 10-year all-cause and AD dementia, with negative predictive values exceeding 90% but low positive predictive values (PPVs). Combining p-tau217 with NfL or GFAP further improved prediction, with PPVs reaching 43%. Our findings suggest that these biomarkers have the potential to rule out impending dementia in community settings, but they might need to be combined with other biological or clinical markers to be used as screening tools.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.